Navigating an Increasingly Complex Treatment Paradigm in the Management of Hereditary Angioedema (HAE): Managed Care Considerations for Improved Patient Outcomes

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2022 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from August 1, 2022, to August 1, 2023
 

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.

 

Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
BioCryst and CSL Behring

Description:
Hereditary angioedema (HAE) is a rare autosomal dominant condition characterized by recurrent attacks of edema at different locations of the body. This potentially life-threatening disease affects approximately 1 in 67,000 individuals, with no identified differences in sex or ethnicity. HAE is characterized by recurrent edema attacks and the cutaneous attacks can be disabling, with the skin, gastrointestinal tract, and upper airways are most commonly affected and with a persistent risk to the patient of acute events of laryngeal swelling that may prove fatal if not treated in a timely manner. Angioedema in general can be confused with cellulitis, Graves disease, blepharochalasis, eosinophilic fasciitis, or amyloidosis which can lead to delays in diagnosis, and inappropriate treatment poses the risk of adverse events, unnecessary surgical interventions, a higher burden of misery, and a potentially higher rate of morbidity and mortality. Fortunately for patients with HAE, novel therapies have recently become available in the past few years that have shown improved efficacy and safety with improved administration methods.

Upon completion of this activity, participants will be able to:

  • Differentiate the various types of hereditary angioedema (HAE), the pathophysiology, and the clinical and economic burden of disease

  • Examine the challenges in diagnosing HAE and the various definitive laboratory tests

  • Analyze the latest data on the efficacy, safety, and administration of current and emerging treatment options for HAE

  • Discuss the evolving role of C1-INH replacement therapy in the management of HAE

  • Assess novel administration methods for novel therapies and how they are changing the treatment paradigm

  • Explore the role of managed care professionals in the development of evidence-based clinical protocols

     

Faculty: William R. Lumry, MD
Clinical Professor of Internal Medicine
University of Texas Southwestern Medical School
Medical Director, AARA Research Center
Private Practice, Allergy and Asthma Specialists of Dallas

Disclosure:

(Relevant Financial Relationships with Ineligible Companies in the Last 24 Months):
Dr. Lumry has served as a consultant for Accordant, BioCryst, Biomarin, CSL Behring, Express Scripts/CVS, Fresenius Kabi, Intellia, Kalvista, Magellan, Optum, Pharming, Pharvaris, and Shire/Takeda. He has served on the speaker's bureau for BioCryst, CSL Behring, Optinose, Pharming, Shire/Takeda, Grifols, Astra Zeneca, Sanofi/Regeneron, and GSK. He has received grant/research support from ALK , BioCryst, CSL Behring, Gossamer, Grifols, Ionis, Kalvista, Kedrion, Shire/Takeda, Pharvaris, Teva. His presentation has been peer reviewed for any bias.
Planning Committee: Bill Williams, MD has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jeremy Williams has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships with an ineligible company in the last 24 months to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
BioCryst and CSL Behring


NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue